ProVise Management Group’s Quest Diagnostics DGX Stock Holding History

ProVise Management Group’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3,581	Closed	-$408K	–	293
2020 Q2	$408K	Sell	3,581 -498	-12%	-$52.8K	0.06%	193
2020 Q1	$328K	Sell	4,079 -13	-0.3%	-$1.35K	0.06%	209
2019 Q4	$437K	Buy	4,092 +1,678	+70%	+$175K	0.05%	213
2019 Q3	$258K	Buy	+2,414	New	+$248K	0.03%	259
2017 Q4	–	Sell	-3,477	Closed	-$326K	–	317
2017 Q3	$326K	Buy	+3,477	New	+$369K	0.05%	249

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

ProVise Management Group's DGX Position: Q3 2020 in Review

ProVise Management Group sold out of Quest Diagnostics (DGX) in Q3 2020, closing a stake of 3,581 shares — an estimated $408K sold.

ProVise Management Group first reported a position in DGX in Q3 2017 and held it in 5 quarters. The position peaked at $437K in Q4 2019. 757 funds tracked by Wall St. Rank hold DGX as of Q3 2020.

ProVise Management Group reported no remaining Quest Diagnostics position as of Q3 2020 after selling out during the quarter.
ProVise Management Group sold 3,581 Quest Diagnostics shares in Q3 2020, an estimated $408K.
ProVise Management Group first reported a position in Quest Diagnostics in Q3 2017 and held it in 5 quarters.
ProVise Management Group's Quest Diagnostics position peaked at $437K in Q4 2019.
757 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2020.

Based on ProVise Management Group's 13F filing for Q3 2020, filed 26 Oct 2020.